Heritage Medical Systems and AbbVie Ventures took part in genome editing technology developer Caribou Biosciences' first funding round in five years.
Caribou Biosciences, a US-based gene-editing technology spinout of University of California (UC) Berkeley, closed a $115m series C round on Wednesday featuring pharmaceutical firm AbbVie and healthcare provider Heritage Medical Systems.
The round was co-led by Farallon Capital Management, PFM Health Sciences and Ridgeback Capital Investments, while AbbVie took part through its corporate venture capital unit, AbbVie Ventures.
Cancer charity Leukemia and Lymphoma Society’s Therapy Acceleration Program also invested, as did Adage Capital Partners, Avego Bioscience Capital, Avidity Partners, Invus,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
